MicroPort Scientific Corporation

2024 Interim Results

30 August 2024

MicroPort微创

Disclaimer

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, "anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

Contents

Strong Results Underpinned by Strategic Focus and Transformation Efforts

Transformation Underway

Reshaping our business with full P&L responsibility and to create shareholder value

Strategic Priorities	1H2024 Progress
Category Leadership	■ Revenue$558.7 mn ▲17.0%YOY ■ Leading market share in domestic for major segments
Meaningful Innovation	■ 31 NMPA， 11 CE Mark， 4 FDA approvals YTD ■ 4 Green Paths YTD, 34 in total，No.1 in industry for 9 consecutive years ■ Firesorb® obtained NMPA approval
Global Expansion	■ Going-abroad business revenue ▲44.0%YOY ■ Cardio. ▲56.3%YOY Endo. ▲65.0%YOY Neuro. ▲87.0%YOY Structural Heart ▲29.2%YOY Surgical Robots ▲293.2%YOY
Unlock Efficiency	■ Total Operating Exp. ratio significantly dropped from 94% to 64% YOY ■ R&D Exp. ratio substantially reduced from 39% to 21%YOY
Narrowed Strategic Focus	■ Divestment of non-core business & asset ■ Shut down R&D projects at early stages based on evaluation

Non-HKFRS Net Loss Substantially Reduced by ▼63.1%YOY

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

Positive Momentum Across Business Segments

Rapid Revenue Growth

Segment	Revenue	YoY Changes	China Revenue YoY Changes
Orthopedics	$126.3mn	▲9.0%	▲32.5%
CRM	$113.4mn	▲5.6%	▲61.5%

Segment	Revenue	YoY Changes	Going-abroad Revenue YoY Changes
Cardiovascular	$93.3mn	▲13.4%	▲56.3%
Endovascular	$110.4mn	▲26.3%	▲65.0%
Neurovascular	$57.1mn	▲36.5%	▲87.0%
Structural Heart	$31.1mn	▲26.7%	▲29.2%
Surgical Robots	$10.0mn	▲117.0%	▲293.2%

Diversified Business

➢ Revenue by Segment



➢ Revenue by Geography



Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

MicroPort®

Substantially Expense Reduced & Cost Effectiveness Increased

Improved Operating Efficiency



Strict Cost Control Across Key Items



Non-HKFRS Adjusted Net Loss Substantially Narrowed



Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

Expanding Our International Presence With Broad-based Capabilities



Possession of Comprehensive Product Portfolio

Established Global Innovation Network System

Recognized Overseas Clinical Trial Evidence

Extensive & Profound Distribution Channel

Leveraging Inter-Group Synergy

Tapping into Diversified Markets

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approval; 3. Registration data as of August 30, 2024.

Contents

Cardiovascular Business: Net Profit Substantially Increased by 279.4%YOY

Most Complete Product Pipeline In Coronary Field

Key Financials



Business Highlights

China

- **1H24 revenue up 4.4%YOY**, among which the DES products growth **are higher than the market level, further enhanced its position of No.1 market share**
- **Hospital coverage expanding:** DES portfolio has accumulatively entered **3,500+** hospitals, achieveing stable growth in market share
- **The new generation** of bioresorbable scaffold **Firesorb®** obtained **NMPA approval**
- Atherectomy Wire obtained **NMPA approval**

Non-China

- **1H24 revenue up 56.3%YOY, stong growth achieved in EMEA (up 107.9%YOY) Asia-Pacific (excluding China, up 43.4%YOY) and Latin America (up 6.1%YOY)**
- **Extensive sales network**: DES sales cover over **80+** countries and regions
- **Diversified & flexible product portfolio** to maintain a leading market position

Complete & Diversified Product Pipeline

Diagnostic Device

 Argusclarity® Insight-100 Optical Coherence Tomography System ◆ NMPA approval	 Argusclarity® Insight-100h Optical Coherence Tomography System ◆ NMPA approval
 Soul-Man™ Digital Subtracting Angiography System ◆ NMPA approval	 Decypher® Intravascular Ultrasound Imaging System Upcoming approval by NMPA

Therapeutic Device

Active

 Integrated Coronary Intravascular Lithotripsy System Upcoming approval by NMPA	 Integrated Coronary Transluminal Rotational Atherectomy System Upcoming approval by NMPA
 Firebird2® Rapamycin-Eluting Coronary Cocr Stent System ◆ NMPA approval	 Firehawk™ Rapamycin Target Eluting Coronary Stent System ◆ NMPA approval

Non-active

 Firesorb® Bioresorbable Rapamycin Eluting Coronary Scaffold System ◆ NMPA approval	 Coronary Sirolimus Eluting Balloon Catheter Upcoming approval by NMPA
 Pioneer™ PTCA Balloon Catheter ◆ NMPA approval	 Firefighter™ PTCA Balloon Catheter ◆ NMPA approval
 AncherV® Exchange Device ◆ NMPA approval	 Coronary Scoring Balloon Catheter Upcoming approval by NMPA
 Interline™ Guiding Catheter ◆ NMPA approval	 Bilumos® Dual-lumen Catheter ◆ NMPA approval

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

MicroPort®

Orthopedics Business: Positive EBITDA Achieved

Revenue Increased By 9.0% YoY

Non-China Business

Revenue



Breakdown by region



Business Highlights

- **1H24 revenue up 6.4%YOY,** continuously improving global supply chain with suppliers being proactively diversified, backorders back to normal operating levels
- **Strong growth in the international markets (EMEA up 19.5%YOY, Japan up 8.0%YOY)** while US declined (-4.5%YOY) under short-term pressure for commercial penetration due to delayed impact from historical backorders
- **Sales revenue of Knee portfolio up 12.5%YOY**, driven by the growing recognition of the premium Medial Pivot Knee system, as well as the successful execution of SkyWalker™ commercial strategy
- SkyWalker™ & Evolution® application with **~300 case of TKA** surgeries performed in **10+** hospitals/ institutions in US and Europe
- **New Products launched:**
  - (Knee) Kinematic Alignment, CCK Revision, Evolution NitrX
  - (Hip) Xelha AR navigation, Dynasty Dual Mobility, Gladiator HA Coated Modular Stem System

China Business

Revenue



Joint products



Business Highlights

- **1H24 revenue up 32.5%YOY**, driven by rapid growth in both implantation volume and sales volume of hip and knee joint products
- Further expanded hospital coverage with regional coverage efficiency strategically enhanced
- Strict implementation of cost-control measures, GPM improved **35 ppts**
- **New Products launched:**
  - Evolution® CCK Knee System and zirconium-niobium femoral condyle obtained NMPA approval, enhanced ex-VBP product portfolio

Products newly approved for marketing

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

CRM Business: EBITDA significantly improved

Revenue Increased By 5.6%YoY

Non-China Business

Revenue

USD: million



Business Highlights

- **1H24 revenue up 1.3%YOY**
  - upstream parts supply problem has been comprehensively solved
- **Expediting market entry:**
  - CE Approval for TALENTIA and ENERGYA defibrillators, cardiac resynchronization therapy
  - defibrillators (CRT-Ds), and XFine™ leads
  - TALENTIA ICDs and CRT-Ds approved in Australia
  - EDIS and GALI defibrillator systems approved in Cyprus
- **1st commercial implantation :**

High Voltage	Low Voltage
• TALENTIA™ CRT-D in Europe. • first GALI™ CRT-D SonR® system in Japan	• Alizea™ Bluetooth® pacemaker system in the US

China Business

Revenue

USD: million



Key products

USD: million



Business Highlights

- **1H24 revenue up 61.5%YOY**, with revenue of pacemakers **up 50.8%YOY**; revenue of leads **up 64.6%**
- **Accelerated market penetration** driven by continuous bids winning in VBP tenders, further consolidate **Top 1** market position among domestic pacemakers
- **GPM** improved by **22** ppts led by proactive dynamic adjustment of product mix and continuous efforts in reduction of costs
- **Further enriched product portfolio strengthens competitive position:** NMPA approval obtained for
  - imported 1.5T/3T full-body MRI compatible ENO™ pacemaker, bridged the intergenerational divide with MNCs, offering premium choices to Chinese patients
  - the domestic 1.5T/3T full-body MRI compatible pacemaker

Products newly approved for marketing

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

Endovascular Business

Key Financials



Business Highlights

China

- **1H24 revenue up 23.6%YOY**, key products recorded steady growth, accelerated hospital entry of new products
- **Innovative products approved in recent years accelerate market penetration**: Castor®, world's first-in-class thoracic branch stent-graft system, covered **1,100+** hospitals, Minos® covered **nearly 900** hospitals, Reewarm® PTX covered **1000+** hospitals, Fontus® covered **200+** hospitals; Talos® covered **nearly 300** hospitals since approval
- **Further enriched product pipeline:** L-REBOA®, Vewatch®, Vepack®, Vflower®, ReeAmber® were approved for marketing by the NMPA

Non-China

- **1H24 revenue up 65.0%YOY**, core products accelerate the development and layout of overseas markets
- **Rapid progressing global launch of core products**: Castor® entered into **19** countries, Minos® entered into **21** countries, Hercules® Low Profile entered into **22** countries
- **Swiftly advancing overseas sales channel**: newly developed **3** countries, innovative products covered **34** markets accumulatively, across EU, Latin America and Southeast Asia
- **Achieved significant progress for R&D projects: 8** new certificates were obtained in overseas markets; Cratos® received the EU Customized Certificate

	Product	Pre-clinical	Clinical	Registration
Aortic Intervention	L-REBOA® Aortic Occlusion Balloon Catheter			✓ Obtained **NMPA** approval
	Cratos® Branched Aortic Stent-Graft System			• Submitted for **NMPA** review • Awarded the EU Customized Certificate
	Aegis® II Abdominal Aortic Stent-Graft System		• Conducting pre-market clinical trial	
	Hector® Multi-branched Aortic Stent-Graft System		• Conducting FIM clinical trial	
	Aortic Tear Flow-Restriction Stent		• Conducting FIM clinical trial	
Peripheral Venous Intervention	Vflower® Venous Stent System			✓ Obtained **NMPA** approval
	Vewatch® Vena Cava Filter			✓ Obtained **NMPA** approval
	Vepack® Filter Retriever			✓ Obtained **NMPA** approval
	Fishhawk® Mechanical Thrombectomy Catheter		• Completed pre-market clinical trial	
Peripheral Arterial Intervention	ReeAmber® Balloon Dilation Catheter			✓ Obtained **NMPA** approval
	Ryfle® Fibered Embolization Coil			• Submitted for **NMPA** review
	Below-The Knee Drug Coated Balloon Catheter		• Conducting pre-market clinical trial	
Oncological Intervention	HepaFlow® TIPS Stent Graft System		• Completed pre-market clinical trial	
	Transjugular Liver Access Set			• Submitted for **NMPA** review
	Polyvinyl Alcohol (PVA) Embolic Microspheres		• Conducting pre-market clinical trial	

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

MicroPort®

Neurovascular Business

Key Financials



Business Highlights

China

- **1H24 revenue up 33.8%YOY**, key products recorded steady growth, accelerated hospital entry of new products
- **Coverage of high-quality hospitals accelerates market penetration**: approximately **300** hospitals have been newly covered, with a total coverage of about **3300** hospitals, accumulated support for approximately **190,000** neuro-interventional surgeries
- **Core product sales boost market share growth:** NUMEN® Coil and APOLLO™ Intracranial Stent benefited from winning the VBP bids, which accelerated the development of new markets; the number of X-track® admitted to hospitals doubled, and clinical use increased by approximately **800%YOY**

Non-China

- **1H24 revenue up 87.0%YOY**, achieved a breakthrough in international business, especially in Asia Pacific, Latin America and EMEA
- **Worldwide commercialization process accelerated:** a total of 8 products that have been launched into the overseas market, and have been commercialized in **21** overseas countries, covering 9 of the top 10 countries worldwide in terms of the number of neuro-interventional procedures
- **Japan**: NUMEN® Coil has entered more than **240** local hospitals
- **France**: NUMEN® Coil achieved **first** commercial clinical application
- **Brazil**: Tubridge® and Neurohawk® achieved **first** commercial implantation/ usage
- **Argentina:** Tubridge® and X-track® achieved **first** commercial implantation/ usage

	Product	Pre-clinical	Clinical	Registration
Hemorrhagic Stroke	Tubridge Plus® Flow-diverting Stent			✓ NMPA approved in Aug 2024
	Numen Silk® 3D Electroically Detachable Coil			✓ NMPA approved • FDA approval expected in 2024
	Numen Uni® Electroically Detachable Coil			• NMPA approval expected in 2024
	NuFairy™ Absorbable Coil Embolization System		• Conducting clinical trial	
	Rebridge® Intracranial Visualized Stent		• Conducting clinical trial	
CAS	Safecer™ Embolic Protection Device			✓ NMPA approved in Jun 2024
	Pathfinder™ Carotid Artery Dilatation Catheter			✓ NMPA approved in Apr 2024
	Intracranial Drug-Coated Balloon Catheter System		• Conducting clinical trial	
	Intracranial Autodistensible Drug Stent	• Design Validation		
	Intracranial Bulbar Expansion Drug Stent	• Design Validation		
AIS	Neurohawk® Pass17/21 Stent Thrombectomy Device			✓ NMPA approved in Jul 2024
	NeuroGuard® Balloon Protection Guide Catheter			✓ NMPA approved in Jan 2024
Access Product	17 Microcatheter	• Design Validation		

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

MicroPort®

Structural Heart Business

Key Financials



Business Highlights

China

- **1H24 revenue up 26.4%YOY**, primarily attributable TAVI products and procedural accessories in the PRC owing to the increased hospital penetration
- **Focusing on enhancement of TAVI accessibility in China**: new access to **50** hospitals brought the Company's coverage to more than **600** hospitals, implantation volume increased by around 10%YOY
- **Official business expansion into stroke prevention in patients with nonvalvular atrial fibrillation:** acquired 51% equity of MP CardioAdvent, and the first batch commercial implantations of the self-developed AnchorMan® LAAC System has been completed up to date after receiving approval by the NMPA in January, 2024

Non-China

- **1H24 revenue up 29.2%YOY**, core products accelerate the development and layout of overseas markets
- **Rapid progressing global launch of core products**: **VitaFlow Liberty® obtained CE mark** and achieved commercial implantation; also received registration approvals in Hong Kong, Saudi Arabia, Belarus and Malaysia; TAVI products have entered nearly **100** hospitals in Argentina, Colombia, Thailand, Russia, Chile and Switzerland
- **Successfully integrated LAA portfolio:** Alwide® Plus reached milestone achievements in emerging markets; CE registration of Alwide® Plus, AnchorMan® LAAC System and AnchorMan® LAA Access System entered key approval process

	Product	Pre-clinical	Clinical	Registration
TAVI	VitaFlow Liberty®	✓ Obtained **NMPA** approval ✓ Obtained **CE** approval		
TAVI	VitaFlow Liberty® Flex	• NMPA Registration in progress		
TAVI	VitaFlow® IV	• Design stage		
TAVI	VitaFlow® Balloon Expandable	• Design stage		
Accessories	Alwide® Plus Balloon Catheter	• CE Marking and registration in emerging markets in progress		
Accessories	AccuSniper™ Double Layer Balloon Catheter	✓ Obtained **NMPA** approval		
Accessories	Alpass® Catheter Sheath II	• Submitted for **NMPA** review		
TMV	Replacement product *(Self-developed)*	• Progressing FIM study		
TMV	AltaValve™ - Replacement product *(Partnership with 4C Medical)*	• Received breakthrough and IDE approval of FDA		
TTV	Replacement product	• Design Stage		
LAA products	AnchorMan® Left Atrial Appendage Closure System	✓ Obtained **NMPA** approval • Submitted for **CE** review		
LAA products	AnchorMan® Left Atrial Appendage Access System	✓ Obtained **NMPA** approval • Submitted for **CE** review		

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

Product admitted to NMPA Green Path

MicroPort®

Surgical Robot Business

Key Financials

Revenue



Total Net Loss



Business Highlights

- **1H24 revenue up 65.3%YOY**, recorded robust sales growth and rapid pace of commercialization
- **Leading position among domestic brands**

China

Toumai®	R-ONE®
• **7** units of new commercial installation • Overall commercial installation base reached **20** units to date, **No.1** among domestic brands	• **2** units of commercialized installation following the NMPA approval in Dec 23

- **1H24 revenue up 293.2%YOY**, overseas markets reached a milestone in commercialization, **Toumai® obtained CE Mark**
- **Ambitious Overseas Penetration**

Non-China

Toumai®	SkyWalker™
• Successfully completed the **first 2** commercial installations with revenue breakthrough • Received over **10** units of overseas orders up to date • Conducted **~100** clinical operations in overseas hospitals up to date • Created **over 20** records of 1st remote surgery in China and globally	• Sales unit **doubled** YoY on the leverage of synergies with Orthopedics Business • Accumulatively received nearly **30** overseas orders up to date • Expanded to cover **20+** countries across **5** continents

	Product	Pre-clinical	Clinical	Registration
Laparoscopic	Toumai® Laparoscopic Surgical Robot			✓ Obtained NMPA approval ✓ Obtained CE marking
	Toumai® Remote Laparoscopic Surgical Robot		• Conducting Clinical trial/ Clinical Evaluation	
	Toumai® Single-arm Laparoscopic Surgical Robot		• Submitted for **NMPA** review	
	DFVision® 3D Electronic Laparoscope			✓ Obtained NMPA approval ✓ Obtained CE marking
Orthopedic	SkyWalker™ Orthopedic Surgical Robot			✓ Obtained NMPA approval ✓ Obtained CE& FDA& ANVISA& TGA & CDSCO approval
Natural Orifice	Trans-bronchial Surgical Robot		• Conducting Clinical trial/ Clinical Evaluation	
Panvascular	R-ONE® Panvascular Surgical Robot			✓ Obtained NMPA approval
Percutaneous	iSR'obot® Mona Lisa Robotic Transperineal Prostate Biopsy System			✓ Obtained NMPA approval

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

MicroPort®

Contents

Consolidated Financial Performance

Revenue

USD: million



Gross Profit Margin

Operating Expenses

USD: million



Non-HKFRS Adjusted Net Loss& Total Net Loss

USD: million



Note: revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies

MicroPort®

Operating Expenses

R&D Expenses

USD: million



R&D expenses decreased by 38.6%YOY

- Due to the proactive cost control and resource focus measures to prioritize and focus on core projects and improve R&D efficiency

Administrative Expenses

USD: million



Administrative expenses decreased by 12.6%YOY

- Due to the Group's effective cost control and scale of operations

Sales & Marketing Expenses

USD: million



Sales & marketing expenses decreased by 8.0%YOY

- Due to efforts to strengthen the synergy and interconnectivity between overseas and domestic sales platforms.

Eyes for greatness
Hands on details

MicroPort®

Consolidated Income Statement

USD'000	2024 1H	2023 1H	Var.
Revenue	558,702	482,605	15.8%
Cost of sales	(228,122)	(194,189)	17.5%
Gross profit	**330,580**	**288,416**	**14.6%**
Other net income	(68)	17,039	-100.4%
Research and development costs	(115,033)	(187,334)	-38.6%
Distribution cost	(156,150)	(169,800)	-8.0%
Administrative expenses	(83,785)	(95,890)	-12.6%
Other operating costs	(12,348)	(12,374)	-0.2%
Loss from operations	**(36,804)**	**(159,943)**	**-77.0%**
Finance cost	(48,416)	(37,256)	30.0%
Gain on disposal of subsidiaries	6,922	2,845	143.3%
Gain on deemed disposal of interest in equity-accounted investees	-	5,437	-100.0%
Share of profits less losses of equity-accounted investees	(8,146)	(17,258)	-52.8%
Loss before taxation	**(86,444)**	**(206,175)**	**-58.1%**
Income tax	(20,230)	(13,746)	47.2%
Loss for the period	**(106,674)**	**(219,921)**	**-51.5%**
Attributable to: Equity shareholders of the Company	**(96,830)**	**(162,618)**	**-40.5%**

Consolidated Balance Sheet

USD'000	30 June 2024	31 Dec 2023	Var.
Non-current assets			
Investment properties	6,087	6,256	-3%
Property, plant and equipment	978,657	1,004,573	-3%
Intangible assets	236,699	234,435	1%
Goodwill	147,271	149,393	-1%
Equity-accounted investees	375,085	372,637	1%
Financial assets measured at fair value through profit or loss ("FVPL")	8,479	10,003	-15%
Derivative financial instruments	-	3,574	-100%
Deferred tax assets	30,366	31,382	-3%
Other non-current assets	109,022	109,705	-1%
Total non-current assets	**1,891,666**	**1,921,958**	**-2%**
Current assets			
Inventories	407,912	414,868	-2%
Trade and other receivables	390,504	310,648	26%
Pledged deposits and time deposits	170,948	225,352	-24%
Cash and cash equivalents	740,097	1,019,551	-27%
Financial assets measured at FVPL	196,122	40,028	390%
Total current assets	**1,905,583**	**2,010,447**	**-5%**
Current liabilities			
Trade and other payables	411,693	448,342	-8%
Contract liabilities	18,464	18,770	-2%
Lease liabilities	47,470	46,915	1%
Interest-bearing borrowings	317,891	295,438	8%
Income tax payable	11,648	4,985	134%
Convertible bonds	103,154	549,470	-81%
Total current liabilities	**910,320**	**1,363,920**	**-33%**

Consolidated Balance Sheet (cont'd)

USD'000	30 June 2024	31 Dec 2023	Var.
Non-current liablities			
Interest-bearing borrowings	801,523	508,330	58%
Lease liabilities	74,107	85,327	-13%
Deferred income	50,110	42,344	18%
Convertible bonds	341,841	213,267	60%
Contract liabilities	26,733	27,669	-3%
Other payables	275,202	262,865	5%
Deferred tax liabilities	24,343	25,686	-5%
Derivative financial instruments	5,117	-	N/A
Total non-current liablities	**1,598,976**	**1,165,488**	**37%**
CAPITAL AND RESERVE			
Share capital	18	18	-
Reserves	699,795	757,801	-8%
Total equity attributable to equity shareholders of the Company	**699,813**	**757,819**	**-8%**
Non-controlling interests	588,140	645,178	-9%
Total equity	**1,287,953**	**1,402,997**	**-8%**